​​Publications:

​​

• ​Shi et al. Cancer Research (2023).  A cell surface-binding antibody atlas nominates a MUC18-directed antibody-drug conjugate for targeting melanoma.  https://doi.org/10.1158/0008-5472.CAN-23-1356

​

• Weng et al. Molecular Cancer Therapeutics (2023). 22:1013-1027.  AMT-562, a Novel HER3-targeting Antibody-Drug-Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing tumors. https://doi.org/10.1158/1535-7163.MCT-23-0198

​

• Weng et al. Cancer Discovery (2023). 13:950-973.  Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. https://doi.org/10.1158/2159-8290.CD-22-1368

​

• Wang et al. Sci. Adv. (2020). 6:eaax2271  An array of 60,000 antibodies for proteome-scale antibody generation and target discovery.   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065887/pdf/aax2271.pdf

​

News:

​

• Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting  https://www.prnewswire.com/news-releases/multitude-therapeutics-announces-promising-interim-phase-iii-results-from-the-ongoing-first-in-human-study-evaluating-its-cd44v9-directed-antibody-drug-conjugate-amt-116-in-heavily-pretreated-egfr-wild-type-non-small-cell-lung--302587390.html?tc=eml_cleartime​

• ​Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting https://www.prnewswire.com/news-releases/multitude-therapeutics-announces-encouraging-interim-phase-iii-results-from-ongoing-first-in-human-study-evaluating-its-muc18-directed-antibody-drug-conjugate-amt-253-in-melanoma-and-other-advanced-solid-tumors-at-the-2025-esmo-302588336.html?tc=eml_cleartime              

• Denmark's Adcendo signs $1B biobuck deal for Multitude’s anti-TF ADC Aug 20, 2024  https://www.fiercebiotech.com/biotech/denmarks-adcendo-signs-1b-biobuck-deal-multitudes-anti-tf-adc                                               

• ​OnCusp Therapeutics and Multitude Therapeutics Enter into an Ex-China Licensing Agreement for a Potentially Highly Differentiated CDH6-Targeting Antibody Drug Conjugate.  Jun 08, 2022  https://www.prnewswire.com/news-releases/oncusp-therapeutics-and-multitude-therapeutics-enter-into-an-ex-china-licensing-agreement-for-a-potentially-highly-differentiated-cdh6-targeting-antibody-drug-conjugate-301563898.html

​

​​

​

​​

​